Everyone carries genetic mutations that have the potential to cause a disorder—even if there is no family history of the disorder. And sometimes, these genetic mutations are passed on to their children.
If you’re pregnant or planning to become pregnant, Inheritest provides useful information about risks for certain genetic disorders and allows you to make informed decisions for a current or future pregnancy.
Inheritest is available in four different panels. Click on each of the panels below to view the specific disorders for which each panel screens.
Inheritest®, 500 PLUS Panel
Includes 525 genes, each associated with a clinically-relevant genetic disorder. It is one of the first carrier screening panels of this size, providing expanded gene coverage to empower you with even more relevant genetic information.
Learn more and see list of disorders
Inheritest®, Comprehensive Panel
Screens for more than 110 disorders, from the more common, such as cystic fibrosis, to the more rare, such as retinitis pigmentosa (also called RP).
Inheritest®, Ashkenazi Jewish Panel
Screens for more than 40 disorders specific to individuals of Ashkenazi Jewish descent.
Inheritest®, Society-Guided Panel
Screens for more than 13 disorders included in the American College of Medical Genetics and Genomics and the American Congress of Obstetricians and Gynecologists guidelines.
Inheritest®, Core Panel
Screens only for cystic fibrosis, spinal muscular atrophy, and fragile X syndrome, some of the most common—and severe—genetic disorders.
Inheritest®, CF/SMA Panel
Screens only for cystic fibrosis and spinal muscular atrophy, the two most common—and severe—genetic disorders. According to the American College of Obstetrics and Gynecologists, all women who are considering pregnancy or are currently pregnant should be offered these genetic tests.1
Other testing options
In addition to carrier screening, we also offer: noninvasive prenatal testing (NIPT) and serum screening for Down syndrome and other conditions; diagnostic testing options for post-pregnancy or further confirmation of screening tests; and hereditary cancer screening.
